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The RCC-SELECT study showed the correlation between single nucleotide poly-
morphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma
(mRCC) patients with first-line interferon-a (IFN-a). In that study, even patients
with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably
improved prognosis. All 180 patients evaluated in the above study were further
analyzed for correlation between OS and demographics/clinicopathological
parameters. OS was estimated using the Kaplan–Meier method. Associations
between OS and potential prognostic factors were assessed using the log-rank
test and the Cox proportional hazards model. The median OS was 42.8 months.
Univariate analysis showed that worse Eastern Cooperative Oncology Group-per-
formance status (ECOG-PS), high T stage, regional lymph node metastasis, distant
metastasis, higher grade, infiltrative growth pattern, the presence of microscopic
vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated
C-reactive protein were significantly associated with OS. Multivariate analysis
revealed that ECOG-PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia
(HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were
jointly significant poor prognostic factors. This is the first study analysing prog-
nostic factors of mRCC patients with first-line IFN-a using large cohort of the pro-
spective study. The present study suggests that first-line IFN-a is still a useful
therapy for mRCC even in the era of molecular targeted therapy.
R enal cell carcinoma (RCC) is one of the most commoncancers. The prevalence of RCC and the mortality rate
have both increased over the past decade.(1) Within the Euro-
pean Union, more than 80 000 new cases were diagnosed in
2012, and there were approximately 35 000 related deaths.(2)
Despite advances in cross-sectional imaging techniques and
increased opportunity for the incidental detection of RCC dur-
ing examination for unrelated diseases, approximately 30% of
RCC patients already harbor metastatic disease.(1) Furthermore,
another 20% of patients who were undertaken nephrectomy
resulted in development of mRCC during follow-up.(3) There-
fore, establishing an optimized treatment strategy for meta-
static disease is a major issue that needs to be addressed in
order to improve survival of RCC patients.
IFN-a was among the most commonly used agents for
mRCC before molecular targeted agents became available.
Although its objective response rate is around 10%(4–7) and the
latest guidelines recommend its usage for clear cell carcinoma
only by simultaneous administration with bevacizumab,(8) for
several reasons it is still used as a single agent for Japanese
mRCC patients. First, it provides a fairly favorable prognosis
in these patients in the cytokine era.(9) Second, patients are
more likely to achieve complete response than if treated with
molecular targeted agents.(10) Third, molecular targeted agents
induce more frequent adverse events in Japanese mRCC
patients than in Caucasian patients.(11)
In our previous case-control association study conducted in
2007, a particular SNP in STAT3, frequently observed in Japa-
nese people compared to Caucasian people, predicts a better
response to IFN-a,(12) supporting the idea that IFN-a is a use-
ful therapeutic option in Japanese mRCC patients. Hence, it is
reasonable to expect that a substantial fraction of Japanese
mRCC patients can still be given IFN-a as a first-line therapy
even in the post-cytokine era. In fact, our recent multi-centre
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prospective study (the RCC-SELECT study) demonstrated that
STAT3-2 (rs1905341) is significantly associated with better
clinical response (complete response, partial response and
stable disease longer than 24 weeks) and better overall sur-
vival (OS) in Japanese mRCC patients with first-line IFN-a
therapy in the post-cytokine era.(10) Notably, in that study,
even the one genotypic cohort (with C/T or T/T in STAT3-2)
with shorter survival exhibited prolonged median OS
(41.8 months) compared to the previous studies (median OS of
the C/C genotype cohort had not been reached at the time of
the previous analysis).(7,9) This suggests that the recent progno-
sis of mRCC patients who received first-line IFN-a therapy
has been significantly improved compared to the cytokine era
regardless of genetic background. However, factors affecting
the prognosis of such patients have not yet been fully studied.
The aim of the present study is to estimate OS and to identify
prognostic factors of mRCC patients whose first-line therapy
was IFN-a in the era of molecular targeted therapy by analyz-
ing the cohort of the RCC-SELECT study.
Materials and Methods
Patients and study design. The RCC-SELECT study was a
multicenter, prospective study evaluating the correlation
between the antitumor effects of IFN-a and 11 SNP in eight
genes in 180 patients who were treated with three doses per
week of IFN-a 5 million IU for 12 weeks or longer. Details of
this study design, including eligibility criteria and endpoints,
have been published previously,(10) and the present study
includes all patients who were eligible in the previous study.
Histology of patients includes 168 clear cell RCC (93.3%), 9
papillary RCC (5.0%) and 3 RCC with unknown histology
(1.7%). The protocol of the present study was approved by the
ethics committees of all the clinical sites, and all patients pro-
vided written informed consent.
Statistical analysis. Overall survival was calculated from the
date when the first IFN-a administration was given to the date
of death as a result of any cause or the date of the last follow-
up. OS was analyzed using the Kaplan–Meier method, and
median OS and hazard ratio along with 95% confidence limits
are described. Associations between OS and potential prognos-
tic factors were assessed using the log-rank test in univariate
analysis. Two-sided P < 0.05 was considered significant. A
stepwise Cox proportional hazards model was performed to
determine a combination of factors that were jointly signifi-
cantly associated with OS. Statistical analyses were performed
with SAS v.8.2 (SAS Institute, Cary, NC, USA).
Results
A total of 211 patients with mRCC were enrolled in the previ-
ous study, and 203 patients were judged to be eligible, whose
characteristics are shown in Table 1.(10) Among those patients,
180 patients who could continue the IFN-a therapy for longer
than 12 weeks were evaluated in the RCC-SELECT study.
Data regarding these 180 patients were further analyzed in the
present study. The median OS of the patients was 42.8 months
(Fig. 1). Then, relationships between patient demographics/
clinicopathological parameters and OS were investigated
(Table 2). Regarding patient characteristics, better ECOG-per-
formance status (ECOG-PS) (0 vs 1) was significantly associ-
ated with longer OS (hazard ratio [HR] = 2.728, P = 0.0006).
Regarding TNM classification, high T stage (T2, T3 and T4 vs
T1) (R = 2.132, P = 0.0298), the presence of regional lymph
node metastasis (N1 and N2 vs N0) (HR = 2.092, P = 0.0033)
and distant metastasis (M1 vs M0) (HR = 1.961, P = 0.0365)
were significantly associated with shorter OS. Regarding
pathological features, while expansive growth pattern was
related to longer OS than infiltrative growth pattern
(HR = 0.571, P = 0.0382), higher grade (G3 vs G1 and G2)
(HR = 2.587, P = 0.0002) and the presence of MVI
(HR = 3.322, P = 0.0004) were significantly associated with
shorter OS. In contrast, neither the presence of sarcomatoid
Table 1. Summary of patient characteristics
Patients, number 180




ECOG performance status, number (%)
0 161 (89.4)
1 19 (10.6)
TNM classification, number (%)
T
T1 39 (21.7)















Site of metastases, number (%)
Lung only 120 (66.7)
Lung and other sites 24 (13.3)
Other sites 36 (20.0)
Fig. 1. Overall survival of 180 patients with metastatic renal cell car-
cinoma treated with IFN-a. Median overall survival (OS) is 42.8 month
(95% confidence interval: 37.1-NA). NA, not available.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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component (HR = 1.657, P = 0.2721) nor sites of metastasis
(lung only metastasis vs metastasis involving other sites)
(HR = 0.688, P = 0.1131) were related to OS. Regarding
laboratory measurements, hypercalcemia (HR = 2.616,
P = 0.0010), anemia (HR = 2.214, P = 0.0008), thrombocyto-
sis (HR = 2.704, P = 0.0009) and elevated C-reactive protein
(CRP) (HR = 2.158, P = 0.0013) were significantly associated
with shorter OS. Elevated lactate dehydrogenase was not asso-
ciated with OS (HR = 3.305, P = 0.0782) probably because
only two patients (1%) exhibited this abnormality. Finally, the
significant variables associated with OS on univariate analysis
were entered into a stepwise Cox regression model, resulting
in the following three factors: ECOG-PS (HR = 3.665,
P = 0.0004), the presence of MVI (HR = 6.428, P = 0.0005)
and hypercalcemia (HR = 2.668, P = 0.0109) (Table 3). Sur-
vival curves for patients with or without those factors are
shown in Figure 2(a–c).
Discussion
This is an extended analysis of the RCC-SELECT study(10)
that confirmed the correlation between the clinical response of
IFN-a therapy for mRCC and a STAT3 SNP (rs1905341). We
observed a marked improvement in patients’ OS (42.8 months)
when compared to patients’ in studies in the cytokine era with
either the same or different racial backgrounds.(7,9,13) It is of
note that the present study is based on the cohort of the first
and hitherto largest prospective study on mRCC patients
whose first-line therapy was IFN-a in the post-cytokine era.(12)
This endorses the accuracy of the results for the following rea-
sons: (i) the collection of precise data regarding the patient
demographics and clinical parameters; and (ii) the careful fol-
low-up until events took place or the observation was finished.
Although there are some differences in patient demographics
(e.g. PS, metastasis sites and frequency of prior nephrectomy)
between the previous and present studies in addition to study
design, the greatest contributing factor is the emergence of
molecular targeted agents. Because the patient enrollment of
the original RCC-SELECT study commenced in December
2006, only 18 months before the introduction of sorafenib and
sunitinib for mRCC in Japan, it is highly likely that the vast
majority of patients enrolled in this study benefited from those
molecular targeted agents following first-line IFN-a therapy.
Notably, Shinohara et al.(14) report in their retrospective study
that the median OS was 38.2 months in the mRCC patients
with the same racial background whose first-line therapy was
cytokine in the era of molecular-targeted therapy. This strongly
supports the result of the present study that the prognosis of
mRCC patients whose first-line therapy was IFN-a has been
remarkably improved.
Intriguingly, in an extended analysis of the AXIS trial com-
paring axitinib versus sorafenib as a second-line treatment for
mRCC, patients previously treated with cytokines including
IFN-a exhibited significantly longer progression free survival
and OS from the start of first-line therapy than those previ-
ously treated with sunitinib in both axitinib and sorafenib trea-
ted groups.(15) This suggests that first-line IFN-a therapy
followed by VEGF-TKI may provide longer survival than
sequencing two different VEGF-TKI in a substantial fraction
of mRCC patients. Considering the result of the landmark trial
comparing IFN-a versus sunitinib by Motzer et al.(16) such a
result appears paradoxical. However, there are some possible
Table 2. Univariate analysis of association between patient









≥65 108 1306 0.981 (0.617–1.562) 0.9363
<65 72 1352
ECOG-PS














M0 39 1453 1.961 (1.031–3.729) 0.0365
M1 138 1282
Growth pattern
Expansive 107 1352 0.571 (0.334–0.977) 0.0382
Infiltrative 34 736
Grade
1 or 2 124 1453 2.587 (1.573–4.254) 0.0002
3 48 728
Sarcomatous component
No 169 1352 1.657 (0.666–4.124) 0.2721
Yes 11 848
Microscopic vascular Invasion
No 50 Not reached 3.322 (1.644–6.713) 0.0004
Yes 112 1070
Site of metastasis
Lung only 120 Not reached 0.688 (0.432–1.096) 0.1131
Others 60 1274
Lactate dehydrogenase
<1.59ULN 168 1352 3.305 (0.807–13.542) 0.0782
≥1.59ULN 2 619
Corrected Ca (mg/dL)
<10 136 1352 2.616 (1.442–4.744) 0.0010
≥10 21 583
Hemoglobin (mg/dL)
≤LLN 89 1070 2.214 (1.372–3.573) 0.0008
>LLN 87 Not reached
C-reactive protein (mg/dL)
<0.3 81 1361 2.158 (1.334–3.491) 0.0013
≥0.3 94 848
Platelet count (/lL)
<400 000 154 1361 2.704 (1.468–4.980) 0.0009
≥400 000 22 524
Table 3. Multivariate analysis of association between patient
factorsand overall survival
Factors P-value Hazard ratio 95% CI
ECOG-PS (0 vs 1) 0.0004 3.665 1.785–7.527
Microscopic vascular
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explanations for this outcome: (i) tumors may have acquired
resistance to VEGF-TKI during first-line sunitinib treatment,
resulting in diminished efficacy with second-line VEGF-
TKI;(17) and (ii) administration of cytokines including IFN-a
provokes generation and persistence of memory T cells that
can recognize tumor epitopes,(18) and such memory T cells
might be ignited by peptide released from dying tumor cells
during VEGF-TKI treatment,(19) resulting in enhancement of
anti-cancer immunity.
In the present study, multivariate analysis revealed that PS,
hypercalcemia and MVI are the independent prognostic factors.
Hypercalcemia is the most frequent paraneoplastic complication
of mRCC, being manifested in up to 20% of RCC patients dur-
ing the course of their disease(20,21) and known to imply a poor
prognosis because of its frequent association with disseminated
disease. Previous reports suggested that humoral factors such as
PTHrP,(22) IL-6(23) and prostaglandins(24) may play roles in
hypercalcemia either directly or indirectly by increasing bone
resorption. Since Motzer et al.(7) identified hypercalcemia as an
independent prognostic factor in mRCC patients treated with
IFN-a, it has been included in other prognosis prediction mod-
els for mRCC from the cytokine era to the target therapy
era.(7,25–28) Interestingly, the largest retrospective analysis so
far regarding prognostic factors for survival in mRCC patients
treated with sunitinib revealed that hypercalcemia is the only
factor among the MSKCC’s criteria(7) for OS in multivariate
analysis.(28) Therefore, hypercalcemia may be a prognostic fac-
tor for metastatic renal cell carcinoma regardless of the type of
systemic therapy.
The importance of MVI as a prognostic factor in RCC is also
well documented in the published literature.(29–31) It is histologi-
cally obvious that MVI requires a local destruction of the venous
wall by the tumor cells. However,, it is also significantly associ-
ated with other prognostic factors such as tumor size, Fuhrman
grade, pathological stage and the presence of sarcomatoid ele-
ments.(29–31) This suggests that MVI is not merely a manifestation
of tumor cell entry into the circulation, but also an indicator of
malignant potential. However, the previous studies indicating
MVI as a prognostic factor were based on the analysis of patients
with clinically localized RCC who underwent radical or partial
nephrectomy, but not those with metastasis at the time of diagno-
sis. Conversely, in previous studies investigating survival of
mRCC patients subjected to systemic therapy, MVI was not
shown as a prognostic factor. This is probably because not all
patients that participated in such studies underwent prior nephrec-
tomy; therefore, analyses regarding the relationship between sur-
vival and histological details of tumors may not have been
feasible. In this sense, this is the first study showing that MVI is a
prognostic factor also in mRCC patients who received systemic
therapy because it includes prior nephrectomy as a study criterion
that enables analysis for correlation between histological factors
such as MVI and overall survival in mRCC patients.
A limitation of the present study is that it only included
patients with limited racial background. Hence, external vali-
dation with other racial backgrounds is needed. The present
study suggests that IFN-a is still a valid agent for mRCC for
first-line treatment even in the era of molecular targeted ther-
apy. For such a treatment strategy, PS, hypercalcemia and
MVI are independent predictors of survival, which will be par-
ticularly useful information for selecting appropriate patients.
Although IFN-a appeared inferior to molecular targeted agents
in the previous clinical trial settings,(16,32,33) we have to recon-
sider its actual efficacy and contemporary role in mRCC treat-
ment in the context of sequential therapy with molecular
targeted agents. Further studies are warranted to identify opti-
mal combination of IFN-a and following molecular targeted
agents for attaining better outcomes.
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